Monroe Biomedical Research (MBR), a dedicated clinical trial site, is growing its footprint to enhance early-phase clinical ...

Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) announces that the Biogenix Molecular Research ...

THE US headquartered clinical research firm Celerion has announced it will relocate its Belfast operation to the new Queen’s ...

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III ...

LINCOLN, Neb.--(BUSINESS WIRE)--Celerion, a global leader in early clinical research, proudly announces a new agreement to relocate its U.K. Phase 1 clinical research operations to iREACH Health.

This story was originally posted in July 2023 and has been updated. Back to top Dr. Balachandran is affiliated with the David M. Rubenstein Center for Pancreatic Cancer Research. The phase 1 clinical ...